Cavdar Mehmet, Nogay Nalan Hakime, Dincer Emine, Karabulut Derya, Onal Muge Gulcihan, Bolat Serkan
Department of Nutrition and Dietetics, Faculty of Health Sciences Inonu University Malatya Turkey.
Department of Nutrition and Dietetics, Faculty of Health Sciences Bursa Uludag University Bursa Turkey.
Food Sci Nutr. 2025 Jul 10;13(7):e70597. doi: 10.1002/fsn3.70597. eCollection 2025 Jul.
The search for alternative, cost-effective, and side-effect-free therapies for hyperlipidemia remains a priority. This study evaluated the effects of probiotic Lacticaseibacillus casei ATCC 393, prebiotic d-tagatose, and their synbiotic combination on hyperlipidemia induced in BALB/c mice via a high-fat, high-cholesterol diet over 12 weeks. During the final 4 weeks, different groups received the respective treatments. Compared to the positive control (PC) group, synbiotic administration (SYN group) significantly reduced serum glucose by 32.8%, total cholesterol by 20.2%, HDL-C by 28.0%, and triglycerides by 42.5% ( < 0.05). Although serum albumin, alanine aminotransferase, and aspartate aminotransferase levels decreased by 3.9%, 5.2%, and 16%, respectively, these changes were not statistically significant ( > 0.05), suggesting preserved liver function without adverse effects. Histological evaluation revealed a significant reduction in microvesicular steatosis and IL-6 immunoreactivity scores exclusively in the synbiotic group, indicating alleviated hepatic lipid accumulation and inflammation. Although synbiotic treatment did not alter overall gut microbiota diversity or species richness, it selectively enriched certain taxa, resulting in dominance of Coprococcus, Parabacteroides, and Bacteroides genera as identified by LEfSe analysis (LDA score ≥ 4, < 0.05). Conversely, Streptococcus and [Ruminococcus] abundances significantly declined from 3.59% to 1.1% and 7.25% to 0.75%, respectively ( < 0.05). Collectively, these findings demonstrate that synbiotic supplementation effectively improves lipid profiles and mitigates hepatic lipid accumulation and inflammation without compromising liver function. The modulation of specific gut microbiota taxa further supports its therapeutic potential. Therefore, the synbiotic formulation investigated herein represents a promising alternative biotherapeutic approach for managing hyperlipidemia.
寻找治疗高脂血症的替代、经济高效且无副作用的疗法仍然是当务之急。本研究评估了益生菌干酪乳杆菌ATCC 393、益生元D-塔格糖及其合生元组合对通过高脂、高胆固醇饮食诱导12周的BALB/c小鼠高脂血症的影响。在最后4周，不同组接受相应治疗。与阳性对照组（PC组）相比，合生元给药（SYN组）显著降低血清葡萄糖32.8%、总胆固醇20.2%、高密度脂蛋白胆固醇28.0%和甘油三酯42.5%（P<0.05）。虽然血清白蛋白、丙氨酸转氨酶和天冬氨酸转氨酶水平分别下降了3.9%、5.2%和16%，但这些变化无统计学意义（P>0.05），表明肝功能得以保留且无不良反应。组织学评估显示，仅在合生元组中微泡性脂肪变性和IL-6免疫反应性评分显著降低，表明肝脏脂质积累和炎症减轻。虽然合生元治疗未改变整体肠道微生物群多样性或物种丰富度，但它选择性地富集了某些分类群，导致通过LEfSe分析确定的粪球菌属、副拟杆菌属和拟杆菌属占优势（线性判别分析得分≥4，P<0.05）。相反，链球菌属和[瘤胃球菌属]的丰度分别从3.59%显著下降至1.1%和从7.25%显著下降至0.75%（P<0.05）。总体而言，这些发现表明，补充合生元可有效改善血脂谱，减轻肝脏脂质积累和炎症，而不损害肝功能。对特定肠道微生物群分类群的调节进一步支持了其治疗潜力。因此，本文研究的合生元制剂代表了一种有前景的治疗高脂血症的替代生物治疗方法。
